Menu

CAPE Patient Engagement & Implementation Evaluation Application

Thank you for your Letter of Intent regarding participation in an opportunity for interested sites to participate in the CAPE Patient Engagement & Implementation Evaluation Pilot Study supported by its principal investigators: Academy of Oncology Nurse & Patient Navigators (AONN+) and The Research Institute of Fox Chase Cancer Center.

The following provides an overview of the study, requirements of participant sites, and information to be submitted no later than Monday, December 21, 2020, at 5:00 pm EST to be considered for participation in the study.

Pilot Study Overview

When diagnosed with cancer, a patient and their family’s quality of life (QOL) is often impacted immediately. QOL includes physical, psychological, social, and spiritual aspects of a patient. Responses such as anxiety and fear after the initial phase of cancer diagnosis and treatment are predominant and can lead to a multitude of barriers exclusively related to QOL. QOL ultimately affects most aspects of a patient’s cancer-care experience, specifically comprehension, coping, and self-care decisions. To address QOL with high-quality care, it is essential to have extensive patient education covering the entire disease trajectory.

  • The CAPE platform for newly diagnosed patients was developed based on extensive experience with patients with non–small-cell lung cancer (NSCLC) and vetting of patient education materials and organizations, and is designed to provide tailored information to patients who are between their cancer diagnosis and the start of first treatment. This is an opportunity to actively engage patients and caregivers by assigning them tasks relevant to their diagnosis, increase productivity, and allow patients to become more involved in their treatment decisions and trajectory, ultimately increasing their QOL. The impact of the CAPE program to facilitate shared decision-making and improve patient satisfaction and reduce anxiety are also impactful to QOL and will be explored with the utilization of this program. As part of this project, sites will have free access to the CAPE platform.

This multisite evaluation study will employ a mixed-methods approach using both qualitative and quantitative data to explore the perceptions and utilization of this comprehensive patient education platform on newly diagnosed NSCLC patients, provider attitudes toward the platform and genomic testing, and implementation of the tool in diverse clinical settings. These insights and findings will guide future efforts to introduce the CAPE platform in a broad array of oncology care.

Primary Objectives

  • Explore patient and provider perceptions about the value and impact of the CAPE platform to educate NSCLC patients about their disease and genomic testing,
  • Explore patient and provider perceptions about genomic testing related to treatment options,
  • Facilitate shared decision-making and improve patient satisfaction and reduce anxiety,
  • Identify potential barriers and solutions for implementation as part of practice in different oncology clinical settings, and
  • Ultimately resulting in a dissemination and implementation guide for future scaling of the platform.

Secondary Objective

  • Describe providers’ perceptions of the CAPE platform and the factors (using the Consolidated Framework of Implementation Research) that might affect its implementation in the future.

Participant Characteristics

Two (2) pilot study participants will be selected within the following care delivery settings.

  • 2 Commission on Cancer–accredited community-based cancer center programs

Overview of Pilot Study Program

Forty newly diagnosed NSCLC patients per site; 2 sites will be selected (rural & urban academic & community cancer centers)

Patient will be recruited to the study at their initial appointment by a nurse/nurse navigator

  • Baseline survey to be completed
  • Utilization of the CAPE platform for 6-8 weeks
  • Participate in a follow-up survey
  • Conduct online survey of the entire thoracic team
  • Conduct virtual focus groups with medical teams
  • Conduct a debriefing with thoracic team at end of project

Application Questions

1. Institution Information
Name
City
State
2. Primary Contact Person
First Name
Last Name
E-mail
Phone
3. Contact Information for Administrator
First Name
Last Name
E-mail
Phone
Do you have your administrator’s approval to participate in this pilot study if chosen?


If administrator name or e-mail identified different from above
First Name
Last Name
E-mail
4. History of Navigation Program
a. How many years has your navigation program been operational?
b. Briefly describe your navigation program and how it evolved since inception.
5. Please select the most appropriate navigation model that represents your program:




Please explain your model:
6. How many thoracic oncology navigators does your cancer program currently have on staff?
7. Does your program have a thoracic oncology physician champion available to support the navigators if your site is chosen for the pilot study?


Physician Champion Name and E-mail
8. How many of your thoracic oncology navigators are members of AONN+?
9. Do navigators meet one-on-one with patients?


10. Is your model virtual where most patient contact is by phone or e-mail?


11. Is your model a combination of direct contact and phone interventions?


If no, please explain.
12. Does the navigator role include educating the patient from the time of diagnosis to initial treatment?


If yes, what types of tools does the navigator utilize to provide patient education?




13. If the patient does not have access to the Internet or e-mail, then how does the navigator provide patient education?
14. Does the navigator have access to a printer to print patient educational material?


15. Does the institution have a patient education review board that must approve patient education materials used by clinicians?


16. Does the navigator participate in distress screening?


If yes,
Does the navigator screen for distress?


What pivotal point is identified for the navigator to screen patients?
Are there additional touchpoints?


If yes, please explain:
What tool does the navigator use for distress screening?


17. What was your cancer program’s analytic caseload per year for newly diagnosed NSCLC patients in 2017, 2018, and 2019?

Program must have the ability to support at least 40 potentially eligible patients in the first 6 months of the study.



18. What electronic health record (EHR) system is used by your institution?
19. What system does the navigator use to document patient interactions and communications?
20. Is this system different from the EHR system used by the physicians and multidisciplinary team?


If yes, does the navigator notes interface with the EHR?


21. Are you aware and agreeable to the terms that AONN+ and The Research Institute of Fox Chase Cancer Center will have access to the program’s data and outcomes for analysis, publication, and presentations?


22. Has your institution been involved in any research studies?


If yes, has the research involved the navigation program? Please explain:
23. The principal investigator has received approval through a central IRB for this study. If your site is selected to participate in this study, will your institution accept central IRB approval?


If no, does your institution require IRB approval? If yes, how long will this process take through your institution’s IRB?
Please upload a letter of support from your institution or practice administrator.
Attached files must be under 2MB. Filenames cannot contain spaces or special characters.

Note: If your site is selected, your program will be required to sign a letter of agreement.

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Thank You to Our Corporate Sponsors and Alliance Partners!

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Silver Corporate Sponsor

    Silver Corporate Sponsor

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • Industry Relations Council Member

    Industry Relations
    Council Member

  • National Alliance Partner

    National Alliance Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Health System Partner

    Health System Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner

  • Industry Relations Alliance Partner

    Industry Relations Alliance Partner